IntrinsiQ Specialty Solutions (Frisco, TX), a part of AmerisourceBergen, has announced the launch of MarketTREND, an interactive, visual tool that provides oncology manufacturers with product performance and market share analytics on a weekly basis.
The tool pulls treatment data from practices’ in-office dispensing and inventory management solutions and compiles it in an online portal, which can be segmented based on the tumor type and/or class of drug the manufacturer is seeking to analyze. Through this system, manufacturers can evaluate the drug’s uptake, market share (e.g., total treatment share vs. new patient starts), how it is performing relative to other drugs in the same category, and how it is affecting the use of those comparable drugs.
Susan Weidner, Senior Vice President of Analytics at IntrinsiQ Specialty Solutions, commented: “Manufacturers are eager to obtain this type of information, especially for products that are highly-targeted, entering crowded markets, or heavily used in the community oncology space. MarketTREND’s reports give manufacturers a significant competitive advantage by providing the valuable insights needed to make more informed decisions about their products more quickly.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
2 Commerce Drive
Cranbury, NJ 08512